Greg Keenan Sells 8,305 Shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) insider Greg Keenan sold 8,305 shares of the stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the transaction, the insider now directly owns 153,484 shares in the company, valued at $1,263,173.32. This trade represents a 5.13 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Greg Keenan also recently made the following trade(s):

• On Monday, March 3rd, Greg Keenan sold 12,239 shares of Aurinia Pharmaceuticals stock. The stock was sold at an average price of $8.00, for a total transaction of $97,912.00.

Aurinia Pharmaceuticals Price Performance

AUPH stock opened at $8.15 on Friday. The stock has a market capitalization of $1.12 billion, a PE ratio of -54.33 and a beta of 1.26. The company’s 50-day moving average is $8.08 and its 200-day moving average is $7.88. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Large investors have recently added to or reduced their stakes in the business. State Street Corp lifted its position in Aurinia Pharmaceuticals by 2.3% in the 3rd quarter. State Street Corp now owns 2,945,060 shares of the biotechnology company’s stock valued at $21,587,000 after acquiring an additional 64,949 shares in the last quarter. Barclays PLC lifted its position in Aurinia Pharmaceuticals by 187.6% in the 3rd quarter. Barclays PLC now owns 219,331 shares of the biotechnology company’s stock valued at $1,607,000 after acquiring an additional 143,072 shares in the last quarter. Blue Trust Inc. lifted its position in Aurinia Pharmaceuticals by 3,041.4% in the 4th quarter. Blue Trust Inc. now owns 6,377 shares of the biotechnology company’s stock valued at $57,000 after acquiring an additional 6,174 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Aurinia Pharmaceuticals in the 3rd quarter valued at about $3,330,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Aurinia Pharmaceuticals by 13.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after acquiring an additional 89,940 shares in the last quarter. Institutional investors own 36.83% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com cut shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.